A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

What this study is about

The purpose of this study is to evaluate the efficacy and safety of standard-of-care chemotherapy and bevacizumab with or without INCA33890 in the first-line treatment of metastatic microsatellite stable colorectal cancer.

Who can join (things the study team will check)

✅ You may be able to join if…

• Stage IV colorectal adenocarcinoma not amenable to curative resection.
• No prior systemic treatment for unresectable or metastatic disease. Participants who received adjuvant or neoadjuvant therapy may enroll if there was no recurrence within 12 months of the end of treatment.
• Measurable disease per RECIST v1.1.
• ECOG performance status of 0 or 1.
• Adequate organ function determined by laboratory results.

🚫 You may not be able to join if…

• MSI-H/dMMR per historical data in the medical record.
• BRAF V600E mutation per historical data in the medical record.
• Untreated and/or progressing CNS metastases.
• History of other malignancy within 2 years.
• Treatment with an anti-PD-(L)1 or other immune checkpoint inhibitor for any indication within the last 3 years.
• Active autoimmune disease that has required systemic treatment in the past 2 years.
• Significant concurrent and/or uncontrolled medical condition.
• History of organ transplant, including allogeneic stem cell transplantation. Other protocol-defined inclusion/exclusion criteria apply.

Where this trial is running

• Ironwood Cancer & Research Centers, Chandler, Arizona, United States
• The University of Arizona Cancer Center, Tucson, Arizona, United States
• Roche Tissue Diagnostics, Companion Diagnostics, Tucson, Arizona, United States
• Memorial Care Orange Coast Medical Center, Fountain Valley, California, United States
• Providence Medical Foundation, Fullerton, California, United States
• Cancer & Blood Research Center, Los Alamitos, California, United States
• University of California Los Angeles Health, Los Angeles, California, United States
• Sarah Cannon Research Institute Scri Oncology Partners, Aurora, Colorado, United States
• Hartford Hospital, Hartford, Connecticut, United States
• George Washington University, Washington D.C., District of Columbia, United States
• Florida Oncology & Hematology, Fort Myers, Florida, United States
• University of Florida Health, Gainesville, Florida, United States

+ 264 more sites.

Who to contact

Incyte Corporation Call Center (US) · 1.855.463.3463 · medinfo@incyte.com

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07284849.